Frequently asked questions about FectoVIR®-AAV
Please feel free to browse the Polyplus-transfection Database to find conditions for specific product, cell line or nucleic acid type:
For more information contact us directly at email@example.com:
The FectoVIR®-AAV structure is confidential and a patent has been filled. PEIpro® and FectoVIR®-AAV are different both in terms of molecular structure and formulation.
You will find starting conditions as well as a range for optimization in the dedicated protocol available in the documentation tab of the FectoVIR®-AAV webpage: https://www.polyplus-transfection.com/products/fectovir-aav/. If you need further information, please contact our scientific support using firstname.lastname@example.org.
We have successfully used FectoVIR®-AAV on suspension HEK-293 derivatives (293T, 293F) and high density derivatives (Expi293™ cells). Beta-testers confirmed that FectoVIR®-AAV works well in several commercial and proprietary suspension HEK-293 subclones.
In house, we produce both AAV-2 and AAV-5. More serotypes have been tested by our beta-testers, with comparable yield improvements.
FectoVIR®-AAV shows a remarquable improvement in terms of viral titers in suspension system and is less efficient in adherent systems for which PEIpro® remains the transfection reagent of choice.
For lentivirus production, we recommend PEIpro® the gold standard for virus production as it is currently the best product for this application, both in adherent and suspension cell culture systems.
A residual test assay is currently under development.
GMP FectoVIR®-AAV will be available in Q2 2021.